Depression remains one of the most prevalent and disabling mental health conditions worldwide. According to the World Health Organization, over 280 million people suffer from depression globally. While traditional antidepressants like SSRIs and SNRIs have been the mainstay of treatment for decades, their slow onset and limited efficacy in some patients have fueled a search for faster-acting and more effective therapies. In 2025, a wave of novel treatments—ranging from psychedelic-assisted therapy to precision-targeted medications—are reshaping the landscape of depression care. This article outlines the most promising new treatments for depression, grounded in the latest research and clinical approvals.
Esketamine (Spravato®)
Esketamine is a nasal spray derived from ketamine, a dissociative anesthetic. It was first approved by the FDA in 2019 for treatment-resistant depression (TRD) and, as of 2025, it has gained expanded approval as a first-line adjunctive treatment for major depressive disorder (MDD).
Mechanism: Esketamine works by antagonizing NMDA receptors, promoting glutamate release and enhancing neuroplasticity—distinct from traditional monoamine-based antidepressants.
Efficacy: Clinical trials show rapid improvements in depressive symptoms, sometimes within hours, with sustained benefits over weeks when combined with an oral antidepressant.
Considerations: Esketamine must be administered in a clinical setting due to the risk of dissociation and blood pressure spikes. However, its fast-acting nature makes it a valuable option for acute suicidal ideation.
Auvelity (Dextromethorphan-Bupropion)
Auvelity is the first oral N-methyl-D-aspartate (NMDA) receptor antagonist approved for depression. It combines dextromethorphan with bupropion, which slows the metabolism of dextromethorphan and enhances its efficacy.
Mechanism: Dextromethorphan acts on NMDA and sigma-1 receptors, while bupropion inhibits dopamine and norepinephrine reuptake.
Efficacy: In clinical trials, Auvelity showed statistically significant symptom relief in as little as one week—considerably faster than traditional SSRIs.
Side Effects: Common side effects include dizziness, nausea, and dry mouth, but overall it is considered well-tolerated.
Zuranolone (Zurzuvae®)
Zuranolone is a novel neurosteroid recently approved for postpartum depression and under investigation for MDD.
Mechanism: It modulates GABA-A receptors to produce calming and mood-stabilizing effects.
Efficacy: A 14-day course of zuranolone has shown significant improvement in depression scores with effects persisting for weeks post-treatment.
Limitations: Its once-daily regimen and potential for sedation are noted, but its rapid action offers advantages for patients needing quick symptom relief.
Psychedelic-Assisted Therapy
Recent years have seen a surge of interest in using psychedelics such as psilocybin and 5-MeO-DMT in therapeutic settings. These substances, when administered under clinical supervision and integrated with psychotherapy, show significant antidepressant effects.
Psilocybin
Mechanism: Psilocybin activates serotonin 5-HT2A receptors, leading to altered perception and enhanced emotional processing.
Efficacy: Studies from institutions like Johns Hopkins University and Imperial College London show that a single or double session of psilocybin-assisted therapy can provide relief lasting up to six months in treatment-resistant depression.
Status: As of 2025, psilocybin has received “breakthrough therapy” designation by the FDA and has been approved for use in countries like Australia and New Zealand under controlled conditions.
5-MeO-DMT
Mechanism: A powerful short-acting psychedelic, 5-MeO-DMT is known for producing profound spiritual experiences in a matter of minutes.
Efficacy: Recent phase 2 trials indicate that a single inhalation session combined with psychological support leads to rapid and sustained remission in a significant percentage of patients.
Next-Generation Drug Candidates
Zelquistinel
A follow-up to the investigational drug rapastinel, zelquistinel is an oral NMDA modulator currently in phase 2 trials.
Mechanism: Enhances synaptic plasticity without the dissociative effects seen in ketamine.
Potential: Shows promise as a fast-acting antidepressant with a more favorable safety profile.
Seltorexant
Seltorexant is an orexin-2 receptor antagonist in late-stage development for MDD, particularly for patients with sleep disturbances.
Efficacy: Phase 2b studies suggest it improves both sleep and depressive symptoms when used as adjunctive therapy.
Brain Stimulation Technologies
Transcranial Magnetic Stimulation (TMS)
TMS is a non-invasive brain stimulation technique that uses magnetic pulses to activate regions of the brain involved in mood regulation.
Advances: The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol has shown up to 80% remission rates in clinical trials.
Transcranial Direct Current Stimulation (tDCS)
A low-cost, portable technology using weak electrical currents to modulate brain activity.
Benefits: Modest symptom relief, but high safety profile and low cost make it accessible for broader populations.
Digital Therapeutics and Precision Psychiatry
Rejoyn (Digital CBT App)
Rejoyn is the first FDA-cleared smartphone app delivering cognitive behavioral therapy (CBT) for MDD.
Features: Offers mood tracking, thought restructuring, and exercises for behavioral activation.
AI and Biomarker-Based Therapies
Pharmacogenetics: Tests such as GeneSight analyze a patient’s genetic makeup to predict which antidepressants they will respond to best.
Biomarkers: Inflammatory markers like C-reactive protein (CRP) are being explored to guide antidepressant selection and predict treatment response.
GLP-1 Receptor Agonists
Originally developed for type 2 diabetes and obesity, drugs like semaglutide (Ozempic/Wegovy) are being repurposed for depression.
Mechanism: Potential anti-inflammatory and neuroprotective effects may underlie improvements in mood.
Status: Preliminary studies show promise, particularly in patients with metabolic syndrome and comorbid depression.
Conclusion
The field of depression treatment is undergoing a transformative period in 2025. With novel rapid-acting drugs, psychedelic-assisted therapy, brain stimulation technologies, and digital solutions, the therapeutic toolbox is more versatile than ever. As science progresses, personalized and multi-modal treatment approaches are becoming the new standard, offering renewed hope to millions of people worldwide.
Dr. Randi Fredricks, Ph.D.
Author Bio
Dr. Randi Fredricks is a leading expert in the field of mental health counseling and psychotherapy, with over three decades of experience in both research and practice. She holds a PhD from The Institute of Transpersonal Psychology and has published ground-breaking research on communication, mental health, and complementary and alternative medicine. Dr. Fredricks is a best-selling author of books on the treatment of mental health conditions with complementary and alternative medicine. Her work has been featured in leading academic journals and is recognized worldwide. She currently is actively involved in developing innovative solutions for treating mental health. To learn more about Dr. Fredricks’ work, visit her website: https://drrandifredricks.com
References
Daly, E. J., et al. (2019). “Efficacy of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.” JAMA Psychiatry, 76(9), 893–903.
Papakostas, G. I., et al. (2022). “A Phase 3 Trial of Auvelity in Major Depression.” The American Journal of Psychiatry, 179(8), 541–550.
Deligiannidis, K. M., et al. (2023). “Zuranolone for Postpartum Depression: Results from a Phase 3 Trial.” Lancet Psychiatry, 10(1), 35–45.
Carhart-Harris, R. L., et al. (2021). “Psilocybin vs Escitalopram for Depression: A Randomized Trial.” New England Journal of Medicine, 384(15), 1402–1411.
Uthaug, M. V., et al. (2022). “The Therapeutic Potential of 5-MeO-DMT in Depression.” Frontiers in Psychology, 13, 832335.
Ghareghani, M., et al. (2021). “NMDA Receptor Modulators in Depression: Focus on Zelquistinel.” Current Neuropharmacology, 19(10), 1745–1754.
Johnson & Johnson. (2024). “Seltorexant Shows Promise as Add-on Therapy in Major Depression.” [Press Release].
Cole, E. J., et al. (2022). “Stanford SAINT: Accelerated TMS for Depression.” American Journal of Psychiatry, 179(2), 142–151.
U.S. FDA. (2024). “Approval of Rejoyn Digital Therapeutic for Major Depressive Disorder.”
Alvares, G. A., et al. (2023). “GLP-1 Receptor Agonists and Mental Health: A Systematic Review.” Nature Reviews Endocrinology, 19(4), 233–244.
McIntyre, R. S., et al. (2023). “Inflammatory Biomarkers in Depression: Clinical Implications.” Molecular Psychiatry, 28(1), 91–101.
